Gryphon Financial Partners LLC Gilead Sciences, Inc. Transaction History

Gryphon Financial Partners LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 13, 2020	SELL	$72.34 - $84.0 $1.61 Million - $1.87 Million	-22,306 Closed	0 $0
Q1 2020 May 05, 2020	BUY	$62.63 - $80.22 $24,237 - $31,045	387 Added 1.77%	22,306 $1.67 Million
Q4 2019 Feb 06, 2020	SELL	$61.62 - $67.78 $9,551 - $10,505	-155 Reduced 0.7%	21,919 $1.42 Million
Q3 2019 Nov 07, 2019	BUY	$62.51 - $69.0 $26,066 - $28,773	417 Added 1.93%	22,074 $1.4 Million
Q2 2019 Aug 09, 2019	BUY	$61.87 - $69.38 $79,936 - $89,638	1,292 Added 6.34%	21,657 $1.46 Million
Q1 2019 May 07, 2019	SELL	$62.53 - $70.05 $206,349 - $231,165	-3,300 Reduced 13.94%	20,365 $1.32 Million
Q4 2018 Feb 11, 2019	SELL	$60.54 - $79.0 $101,586 - $132,562	-1,678 Reduced 6.62%	23,665 $1.48 Million
Q3 2018 Nov 06, 2018	BUY	$71.28 - $78.92 $14,256 - $15,784	200 Added 0.8%	25,343 $1.96 Million
Q2 2018 Aug 14, 2018	SELL	$64.88 - $75.68 $18,944 - $22,098	-292 Reduced 1.15%	25,143 $1.78 Million
Q1 2018 May 14, 2018	SELL	$72.84 - $88.8 $15,806 - $19,269	-217 Reduced 0.85%	25,435 $1.92 Million
Q4 2017 Feb 09, 2018	BUY	$71.15 - $83.52 $1.83 Million - $2.14 Million	25,652	25,652 $1.84 Million

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Gryphon Financial Partners LLC, based on Form 13F filings with the SEC.

Stay updated on Gryphon Financial Partners LLC with notifications on news.